Join our daily newsletter At The Bell to receive exclusive market insights
Late-stage drug developer Paradigm Biopharmaceuticals (ASX:PAR) is preparing for a huge CY26 after landing a key recruitment milestone late last year, bringing in enough participants to hit its expected 25% goal.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content has been prepared as part of a partnership with Paradigm Biopharma Ltd and is intended for informational purposes only.
“Paradigm confirms that it has the required number of participants either enrolled or randomised to support the achievement of the 25% recruitment milestone for the PARA_OA_012 trial,” the company wrote in December.
Many just started their regimes this week, The Market Link understands; Paradigm delayed some start dates so the holidays didn’t interfere with results.
Screening activity across the “PARA_OA_012” trial remains strong, the company also confirmed. A significant pipeline of prospective participants has been identified, with the next milestone – you guessed it, 50% – expected to be completed a lot quicker than Paradigm’s 25% marker took in late CY25.
That will be helped by planned rollouts in Moldova and Hong Kong, where the biopharmaceuticals developer has been setting up screening sites. These should start operating fully a little later this month.
“Importantly, the interim analysis remains on track for mid-2026, with primary endpoint analysis expected in Q4 CY2026,” said Paradigm director Paul Rennie.
All put together, it’s already looking like a “very exciting and pivotal year ahead for Paradigm in 2026,” Mr Rennie said. Goals remain focused on “progressing rapidly” through the stages as recruitment balloons, he added.
Heading into CY26, PAR shares have been selling at 34cps.
Join the discussion. See what HotCopper users are saying about Paradigm Biopharma Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
